Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for PFIZER

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 6
Medicare/Medicaid

Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.

Trade (domestic/foreign)

Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.

Budget/Appropriations

Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.

Defense

Issues related to pharmaceutical manufacturing and development.

Health Issues

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

Taxation/Internal Revenue Code

Tax issues affecting the pharmaceutical industry including international tax; including tax issues under consideration for reconciliation legislation and H.R. 1, One Big Beautiful Bill Act". Vaccine excise tax issues and VICP. P.L. 119-21.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem